Dr. Klopp on the Future of Chemoradiation in Endometrial Cancer

Video

Ann H. Klopp, MD, PhD, an associate professor of radiation oncology at The University of Texas MD Anderson Cancer Center, discusses the future of chemotherapy in combination with radiation for the treatment of patients with endometrial cancer.

Ann H. Klopp, MD, PhD, an associate professor of radiation oncology at The University of Texas MD Anderson Cancer Center, discusses the future of chemotherapy in combination with radiation for the treatment of patients with endometrial cancer.

Going forward, the hope is to better distinguish subsets of patients based on their biology in order to give them a particular type of treatment, explains Klopp. For example, some patients may benefit from immunotherapy, whereas some may benefit from targeted therapy. According to Klopp, the current best evidence suggests that the standard of care should be chemotherapy and radiation combined.

For the patients who only receive chemotherapy and do not receive radiation, there is a 30% risk of having the cancer come back in the pelvis, Klopp says. Sometimes those patients can still get curative radiation treatment, but it is a more intensive type of radiation that does not always work.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,